16 Goodhope Street
Paddington, NSW 2021
Australia
61 1300 995 098
https://regeneus.com.au
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees:
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Karolis Rosickas | Chief Executive Officer | 250k | N/A | N/A |
Prof. Graham Vesey Ph.D. | Chief Scientific Officer & Executive Director | 39.28k | N/A | 1965 |
Dr. Charlotte Morgan Ph.D. | Head of Research & Development | N/A | N/A | N/A |
Ling Leung Hang | Company Secretary | N/A | N/A | N/A |
Regeneus Ltd, a clinical stage regenerative medicine company, develops cell-based therapies for the human health markets with a focus on osteoarthritis and other musculoskeletal disorders, neuropathic pain, and dermatology diseases in Australia. The company's platform technology includes Progenza, a multi-synergistic therapy, which has completed Phase I clinical trial for the treatment of osteoarthritis; and in pre-clinical stage to treat neuropathic pain. It also develops Sygenus that is in pre-clinical stage for the treatment of skin wound healing. The company was incorporated in 2007 and is headquartered in Paddington, Australia.
Regeneus Ltd’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.